SIO submits letters annually to the NCCN, advocating for important changes and updates to the current treatment guidelines. These efforts are led annually by the NCCN Task Force. Download our recent letters below.
View and download Current NCCN Guidelines
NCCN Soft Tissue Sarcoma Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Soft Tissue Sarcoma Guidelines. Authored by Jack Jennings, MD, PhD, Joseph Erinjeri, MD, PhD, and Daehee Kim, MD, this letter requests two specific changes to the NCCN Soft Tissue Sarcoma Cancer Guidelines: 1) the addition of drug-eluting bead chemoembolization as a treatment option for desmoid tumors and transarterial chemoembolization (TACE) as a treatment option for selective extra-abdominal desmoid tumors; and 2) clarifying embolization procedures to include transarterial bland embolization, chemoembolization, and radioembolization for non-lung metastases treatment.
Download the 2023 Letter
Download the 2022 Letter
NCCN Adult Cancer Pain Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines of Adult Cancer Pain. Submitted by Jack Jennings, MD, PhD, Associate Professor, Washington University; Anil N. Kurup, MD, Radiologist, Mayo Clinic; and Majid Maybody, MD, Associate Professor of Radiology, Memorial Sloan Kettering Cancer Center. This letter requests the NCCN Adult Cancer Pain Guideline Panel review eight specific changes and data for inclusion in the management of adult cancer pain.
NCCN Bone Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Bone Cancer Panel. Submitted by Ernesto Santos, MD, Interventional Radiologist, Memorial Sloan Kettering Cancer Center; and Sean Tutton, MD, FSIR, FCIRSE, Interventional Radiologist, UC San Diego Health, this letter requests the NCCN Panel consider the future inclusion of an interventional radiologist to the panel to provide important imaging and minimally invasive expertise and further diversify the committee membership.
Download the 2022 Letter
NCCN Breast Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines of Breast Cancer. Submitted by Amy Deipolyi, MD, PhD, Assistant Professor of Radiology, Memorial Sloan Kettering Cancer Center; and Gary A. Ulaner, MD, PhD, Associate Professor of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center. This letter recommends PET/CT to monitor disease progression rather than specifying it as optional and including embolotherapies for treatment of refractory hepatic metastasis.
NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease. Submitted by Sirish A. Kishore MD, Clinical Assistant Professor of Radiology (Affiliated), Stanford University; Adie Friedman MD, Assistant Professor of Radiology, Mount Sinai Medical Center; and Deepak Sudheendra MD, Assistant Professor of Clinical Radiology, University of Pennsylvania. This Letter requests five specific changes for inclusion to the guidelines for Cancer-Associated Venous Thromboembolic Disease.
Download the 2020 Letter
NCCN Colorectal Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines of Colon and Rectal Cancer. Authored by Bruno C. Odisio, MD, FSIR; Kamran Ahrar, MD; and Juan Camacho, MD, this letter requests four specific changes to the NCCN Colon and Rectal Cancer Guidelines panel centering on the incorporation of image-guided thermal ablation into the main treatment algorithm as well as the creation of “principles of locoregional therapy."
NCCN Hepatobiliary Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines of Hepatobiliary. Submitted by Gregory Nadolski, MD, Assistant Professor, University of Pennsylvania; Sid Padia, MD, Associate Professor, UCLA; Amanda Smolock, MD, PhD; and Beau Toskich, MD, Radiologist, Mayo Clinic. This letter requests the NCCN Guidelines Panel for Hepatobiliary Cancer review five specific changes and data regarding the treatment of HCC.
NCCN Kidney Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Renal Guidelines. Submitted by Ronald S. Arellano MD, Professor of Radiology, Harvard University; Thomas D. Atwell MD, Professor of Radiology, Mayo Clinic; and S. William Stavropoulos MD, Professor of Radiology, University of Pennsylvania. This letter requests the NCCN Kidney Cancer Guideline Panel review four specific changes, including the inclusion of microwave ablation as a thermal ablation option, revise the recommendations for imaging follow-up after thermal ablation, and include thermal ablation as a treatment option in the management of T1b tumors.
NCCN Lung Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Non-Small Cell Lung Guidelines. Authored by Aaron W.P. Maxwell, MD; Patrick W. Eiken, MD; Robert D. Suh, MD, this letter requests six specific changes to the NCCN Non-Small Cell Lung Guidelines panel centering on the incorporation of image-guided thermal ablation into the main treatment algorithm for patients with primary and metastatic NSCLC.
NCCN Neuroendocrine Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Guidelines for Neuroendocrine. Submitted by Etay Ziv, MD, PhD, Memorial Sloan Kettering Cancer Center; Nicholas Fidelman, MD, University of California San Francisco; and Rony Avritscher, MD, UT MD Anderson Cancer Center. This letter requests the NCCN Neuroendocrine and Adrenal Tumors Guideline Panel review data regarding seven specific changes to update the role of liver-directed therapies (LDT) in the clinical practice guidelines in oncology.
NCCN Pancreatic Adenocarcinoma Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Pancreatic Adenocarcinoma Guidelines. Authored by Hooman Yarmohammadi, MD; Govindarajan Narayanan, MD; F. Edward Boas, MD PhD; Vlasios Sotirchos, MD; and Peiman Habibollahi, MD, this letter requests three specific changes to the NCCN Pancreatic Adenocarcinoma Guidelines panel centering on the incorporation of locoregional therapies for patients with locally advanced pancreatic cancer, as a palliative or supportive care option in patients with advanced disease, and therapy for patients with metastatic cancer.
Download the 2023 Letter
Download the 2022 Letter
NCCN Palliative Care Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Palliative Care Guidelines. Submitted by Sean Tutton, MD, FSIR, FCIRSE, UC San Diego Health; Jack Jennings, MD, PhD, FSIR, Washington University Physicians; Gina Landinez, MD, UC San Francisco Health; Neil Resnick, MD FSIR, Emory University School of Medicine; William S. Rilling MD, FSIR, Medical College of Wisconsin; Alan A. Sag, MD, Duke Health; and Anthony Tadros, MD, UC San Diego Health. This letter requests the NCCN Palliative Care Guidelines Panel review the recommendations for inclusion of interventional consultation for pain likely to be relieved with image-guided procedures and inclusion percutaneous transesophageal gastrostomy tube (PTEG) as consideration to palliate nausea and vomiting in the setting of challenging anatomy or intra abdominal metastasis. Additionally, the letter requests that the NCCN Palliative Care Panel consider including an interventional radiologist (IR) on the panel.
NCCN Prostate Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Prostate Cancer Guidelines. Submitted by David A. Woodrum, MD/PhD, Associate Professor of Radiology and Urology, Mayo Clinic; Vijay Ramalingam, MD, Clinical Instructor of Radiology, Harvard; Eric Walser, MD, Professor and Chair of Radiology, UTMB; Lance Mynderse, MD, Associate Professor of Urology and Radiology, Mayo Clinic. This letter requests the NCCN Prostate Cancer Guidelines Panel review the recommendations for inclusion of focused ultrasound ablation, cryoablation, and laser ablation as initial treatment options for very low risk, low risk, and favorable intermediate-risk groups.
Download the 2024 Letter
Download the 2023 Letter